Preclinical studies indicated that ANAVEX3-71 could alter disease characteristics such as cognitive deficits and amyloid and Tau pathology in AD transgenic mice (3xTg-AD), exert beneficial effects on mitochondrial dysfunction, and attenuate neuroinflammation. This evidence concerns the gene MAPT and Alzheimer disease.